Comparison of high‐dose dual therapy with bismuth‐containing quadruple therapy in Helicobacter pylori‐infected treatment‐naive patients: An open‐label, multicenter, randomized controlled trial
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy2022Vol. 42(3), pp. 224–232
Citations Over TimeTop 10% of 2022 papers
Jia‐Lun Guan, Yunlian Hu, Ping An, Qiong He, Hui Long, Lin Zhou, Zhifen Chen, Jian‐Guang Xiong, Shi‐Sheng Wu, Xiangwu Ding, Hesheng Luo, Peiyuan Li
Abstract
High-dose dual therapy for H. pylori eradication had similar efficacy and compliance, fewer adverse events, and lower costs than bismuth-containing quadruple therapy for treatment-naive patients.
Related Papers
- → Clarithromycin Resistance and Eradication of Helicobacter pylori in Children(2001)64 cited
- → Esomeprazole‐based one‐week triple therapy with clarithromycin and metronidazole is effective in eradicating Helicobacter pylori in the absence of antimicrobial resistance(2003)28 cited
- → Lower concentrations of clarithromycin suppress urease activity, motility, and binding to gastric epithelial cells in Helicobacter pylori isolates(2002)4 cited
- One-week triple therapy with esomeprazole, amoxicillin and azithromycin for Helicobacter pylori -positive duodenal ulcer(2011)
- Effect on eradication of Helicobacter pylori with esomeprazole, clarithr-omycin and amoxicillin triple therapy(2004)